AI in Digital Pathology: From Glass Slides to Gigapixel Analysis

Introduction

Radiology, covered in Blog 02 of this series, has become the flagship story of AI in medical imaging, with well over a thousand FDA-authorized devices. Pathology tells a strikingly different story on the same regulatory timeline. Through 2026, only a handful of whole-slide imaging AI algorithms had reached FDA authorization, a small fraction of what radiology has accumulated over the same period. Understanding why reveals something useful about what actually determines how fast a clinical AI field matures.

What Digital Pathology Is

Traditional pathology involves a pathologist examining tissue on a glass slide under a microscope. Digital pathology instead scans the slide into an extremely high-resolution digital image, often called a whole-slide image, which can then be viewed on a screen, shared electronically, and, critically, analyzed by software. A single whole-slide image can be gigapixels in size, far larger than a typical radiology scan, which creates its own computational and storage challenges.

Why Pathology AI Has Lagged Radiology

Several structural factors explain the gap. Digitization itself came later: the FDA didn't clear the first whole-slide imaging system for primary diagnosis until 2017, years after digital radiology was already routine, so pathology labs had less time and less existing digital infrastructure to build AI on top of. Whole-slide images are also vastly larger than a typical radiology scan, creating storage and processing demands that took longer for institutions to solve at scale. And validating a pathology AI tool typically requires expert-annotated ground truth at the level of individual cells or small tissue regions across huge images, a more labor-intensive annotation process than marking a single finding on a radiology scan.

What's Actually Cleared and Working

The devices that have reached FDA authorization concentrate on prostate cancer, an area with a strong evidence base and clear clinical need. One system supports prostate cancer detection with reported specificity above 96% and an AUC near 0.99 in validation studies, while others provide Gleason grading and tumor burden quantification. In 2025, a prognostic tool combining whole-slide biopsy images with clinical data received De Novo authorization specifically to predict which patients would benefit from a particular treatment, a notable step because it moved beyond simple detection into treatment-relevant prediction. FDA-cleared tools also exist for quantifying biomarkers such as Ki-67 and HER2 and for cervical cytology screening. Every one of these tools is designed to support pathologist review, not replace it, and requires final human sign-off, the same pattern seen across every diagnostic AI category in this series.

Where the Broader Field Is Heading

Beyond narrow, cleared diagnostic tools, research is moving toward large foundation models trained on enormous numbers of whole-slide images from multiple institutions, aimed at supporting a wider range of tasks, including rarer cancers that individually lack enough data for a narrow, purpose-built model. This mirrors the multimodal and foundation-model trend covered in Blog 30 of this series, applied specifically to tissue images. These models remain earlier-stage than the narrowly cleared clinical tools described above.

Implementation Considerations for Pathology Labs

• Whole-slide imaging infrastructure comes first. A lab needs validated scanners and an image management system compatible with whatever AI tool is being considered, and validation against College of American Pathologists guidelines for primary diagnosis is a prerequisite most labs need to complete before AI adds meaningful value.
• Storage and computing costs are real and ongoing. Given the size of whole-slide images, these costs should be budgeted as part of any pathology AI initiative, not treated as a one-time setup cost.
• Start with a narrow, well-validated use case. such as prostate cancer detection or a specific biomarker quantification, rather than expecting a single tool to generalize across cancer types.
• Confirm platform compatibility. between a chosen AI algorithm and the whole-slide imaging system already in place, since these aren't always interchangeable.

Bottom Line

AI in digital pathology is real and clinically useful within a narrow set of well-validated applications, concentrated heavily in prostate cancer and specific biomarker quantification tasks. It remains meaningfully behind radiology in regulatory maturity and breadth of coverage, mostly for structural reasons: later digitization, larger and more computationally demanding images, and more labor-intensive validation requirements. Labs considering this technology should treat whole-slide imaging infrastructure as the real first step, with AI as something layered carefully on top of a validated imaging foundation.

This article is educational and does not provide medical advice.

Suggested Internal Links

• Computer Vision Development
• Cloud Solutions

Sources / References

• AI/ML in Digital Pathology and the Software-as-an-IVD Paradigm: 2026 Snapshot — Innolitics
• Translational AI in Whole-Slide Image Cancer Histopathology: State of the Art and Regulatory-Approved Solutions — Frontiers in Digital Health, 2026
• Digital Pathology Imaging Artificial Intelligence in Cancer Research and Clinical Trials: An NCI Workshop Report — PMC
• Digital Pathology and AI: What Oncologists Need to Know — Medscape

CTA

Whether you're modernizing a pathology lab's imaging infrastructure or exploring computer vision for tissue analysis, the underlying data and storage architecture matters as much as the algorithm. Techverse Solutions can help scope that work. Get in touch to discuss your project.